Blood

Vol. 145, Issue 18 Issue 18 2025
18
Articles

Articles in this Issue

How I treat higher-risk MDS

Alain Mina, Rami Komrokji May 01, 2025 pp. 2002-2011 10.1182/blood.2024025271

Abstract Myelodysplastic syndromes/neoplasms (MDS) are a widely heterogenous group of myeloid malignancies characterized by morphological dysplasia, a defective hematopoiesis, and re...

Breathing life into the hematopoietic potential of the lung

Anthony K. Yeung, George J. Murphy May 01, 2025 pp. 1963-1964 10.1182/blood.2025028548

Is β2-glycoprotein I prothrombotic?

Marie A. Hollenhorst May 01, 2025 pp. 1972-1973 10.1182/blood.2025028404

NETs persisting in vasculature undergo self-renewal with consequences for subsequent infection: a mouse model study

Michal Santocki, Anna Such, Dominika Drab et al. May 01, 2025 pp. 2070-2085 10.1182/blood.2024026643

Abstract Although key for pathogen immobilization, neutrophil extracellular traps (NETs) often cause severe bystander cell/tissue damage. This was hypothesized to depend on their pro...

NET self-renewal: vascular Groundhog Day

Rose Binley-Ewing, Paul Kubes May 01, 2025 pp. 1971-1972 10.1182/blood.2024028067

Decoding functional hematopoietic progenitor cells in the adult human lung

Catharina Conrad, Mélia Magnen, Jessica Tsui et al. May 01, 2025 pp. 1975-1986 10.1182/blood.2024027884

Abstract Although the bone marrow is the main site of blood cell production in adults, rare pools of hematopoietic stem and progenitor cells have been found in extramedullary organs....

Microbiota drives colitis in chronic granulomatous disorder

David M. Lowe May 01, 2025 pp. 1966-1967 10.1182/blood.2025028350

Long-term outcomes with single-agent BRAF inhibitor therapy in Erdheim-Chester disease

Gaurav Goyal, Anne S. Reiner, Dana Bossert et al. May 01, 2025 pp. 2100-2103 10.1182/blood.2024028032

Abstract Among 64 patients with Erdheim-Chester disease treated with a BRAF inhibitor (median follow-up 4 years), we found high response rates (85%) but frequent discontinuations (61...

Donor regulatory T-cell therapy to prevent graft-versus-host disease

Everett H. Meyer, Anna Pavlova, Alejandro Villar-Prados et al. May 01, 2025 pp. 2012-2024 10.1182/blood.2024026446

Abstract Allogeneic hematopoietic cell transplantation is a curative therapy limited by graft-versus-host disease (GVHD). In preclinical studies and early-phase clinical studies, enr...

Mixed-phenotype acute leukemia revisited: omics lead the way

Lars Bullinger May 01, 2025 pp. 1969-1971 10.1182/blood.2025028351

When lymphoma mimics adenocarcinoma: signet ring morphology in follicular lymphoma

Xenia Parisi, L. Jeffrey Medeiros May 01, 2025 pp. 2104-2104 10.1182/blood.2025028395

Reactive oxygen species regulate early development of the intestinal macrophage-microbiome interface

Zohreh Mansoori Moghadam, Bei Zhao, Candice Raynaud et al. May 01, 2025 pp. 2025-2040 10.1182/blood.2024025240

Abstract The controlled development of cellular intestinal immunity in the face of dynamic microbiota emergence constitutes a major challenge in very early life and is a bottleneck f...

Defining 2 biologically and clinically distinct groups in acute leukemia with a mixed phenotype

Pallavi Galera, Deepika Dilip, Andriy Derkach et al. May 01, 2025 pp. 2056-2069 10.1182/blood.2024026273

Abstract A mixed phenotype (MP) is a characteristic of de novo MP acute leukemia (MPAL), but it can also be found in other leukemias. It poses substantial classification and manageme...

Protection of β2GPI-deficient mice from thrombosis reflects a defect in PAR3-facilitated platelet activation

Paresh P. Kulkarni, Ravi Kumar Alluri, Matthew Godwin et al. May 01, 2025 pp. 2086-2099 10.1182/blood.2024024469

Abstract Antibodies to β2-glycoprotein I (β2GPI) cause thrombosis in antiphospholipid syndrome; however, the role of β2GPI in coagulation in vivo is not understood. To address this...

Class struggle in DLBCL

Joanna A. Krupka, Daniel J. Hodson May 01, 2025 pp. 1967-1969 10.1182/blood.2024027995

DLB<i>class</i>: a probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphoma

Björn Chapuy, Timothy Wood, Chip Stewart et al. May 01, 2025 pp. 2041-2055 10.1182/blood.2024025652

Abstract Diffuse large B-cell lymphoma (DLBCL) is a clinically and molecularly heterogeneous disease. The increasing recognition and targeting of genetically defined DLBCLs highlight...

Donor regulatory/conventional T-cell grafts for the GVHD win?

Antonio Pierini, John Koreth May 01, 2025 pp. 1964-1965 10.1182/blood.2024028047

Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT

Carmelo Gurnari, Marie Robin, Lionel Adès et al. May 01, 2025 pp. 1987-2001 10.1182/blood.2024025131

Abstract For patients with myelodysplastic neoplasm/syndrome (MDS), allogeneic hematopoietic cell transplantation (allo-HCT) represents the only potentially curative treatment, capab...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page